PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Overview • Comparison by product • Oral drug – Market size and forecast 2017-2022 • IV drug – Market size and forecast 2017-2022 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Vendor focus on expanding reach of IV iron drugs • Growing focus on emerging economies • Counterfeiting of drugs PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Allergan • AMAG Pharmaceuticals • Daiichi Sankyo • PHARMACOSMOS • Vifor Pharma PART 15: APPENDIX • List of abbreviations Exhibit 01: Related market Exhibit 02: Market characteristics Exhibit 03: Global iron drugs market: Segments Exhibit 04: Market definition: Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global iron drugs market: Market size and forecast 2017-2022 ($ mn) Exhibit 08: Global iron drugs market: Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition: Five forces 2017 Exhibit 17: Segmentation by product: Market share 2017-2022 (%) Exhibit 18: Comparison by product Exhibit 19: Oral drug: Market size and forecast 2017-2022 ($ mn) Exhibit 20: Oral drug: Year-over-year growth 2018-2022 (%) Exhibit 21: IV drug: Market size and forecast 2017-2022 ($ mn) Exhibit 22: IV drug: Year-over-year growth 2018-2022 (%) Exhibit 23: Market opportunity by product Exhibit 24: Customer landscape Exhibit 25: Segmentation by geography: Market share 2017-2022 (%) Exhibit 26: Regional comparison Exhibit 27: Americas: Market size and forecast 2017-2022 ($ mn) Exhibit 28: Americas: Year-over-year growth 2018-2022 (%) Exhibit 29: EMEA: Market size and forecast 2017-2022 ($ mn) Exhibit 30: EMEA: Year-over-year growth 2018-2022 (%) Exhibit 31: APAC: Market size and forecast 2017-2022 ($ mn) Exhibit 32: APAC: Year-over-year growth 2018-2022 (%) Exhibit 33: Key leading countries Exhibit 34: Market opportunity Exhibit 35: Vendor landscape Exhibit 36: Landscape disruption Exhibit 37: Vendors covered Exhibit 38: Vendor classification Exhibit 39: Market positioning of vendors Exhibit 40: Allergan: Overview Exhibit 41: Allergan: Operating segments Exhibit 42: Allergan: Organizational developments Exhibit 43: Allergan: Geographic focus Exhibit 44: Allergan: Segment focus Exhibit 45: Allergan: Key offerings Exhibit 46: AMAG Pharmaceuticals: Overview Exhibit 47: AMAG Pharmaceuticals: Business segments Exhibit 48: AMAG Pharmaceuticals: Organizational developments Exhibit 49: AMAG Pharmaceuticals: Key offerings Exhibit 50: Daiichi Sankyo: Overview Exhibit 51: Daiichi Sankyo: Business segments Exhibit 52: Daiichi Sankyo: Organizational developments Exhibit 53: Daiichi Sankyo: Geographic focus Exhibit 54: Daiichi Sankyo: Segment focus Exhibit 55: Daiichi Sankyo: Key offerings Exhibit 56: PHARMACOSMOS: Overview Exhibit 57: PHARMACOSMOS: Business Exhibit 58: PHARMACOSMOS: Organizational developments Exhibit 59: PHARMACOSMOS: Key offerings Exhibit 60: Vifor Pharma: Overview Exhibit 61: Vifor Pharma: Business segments Exhibit 62: Vifor Pharma: Organizational developments Exhibit 63: Vifor Pharma: Geographic focus Exhibit 64: Vifor Pharma: Key offerings

Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, PHARMACOSMOS, and Vifor Pharma.